Catalyst Calendar

Fri, Aug 14, 2026

1 updates

1:00 AM

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

NEW YORK & LYON, France, August 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin...

valneva.com

Thu, Aug 13, 2026

1 updates

VALN

1:00 AM

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering [1] Restructuring program implemented with positive P&L and cash flow impacts expected in the second...

valneva.com

Wed, Jul 22, 2026

1 updates

VALN

11:45 AM

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update....

valneva.com